Computational study on gabapentin as a potential therapy for partial seizures

Abstract

US Food and Drug Administration (USFDA) approved gabapentin as an adjuvant treatment for refractory partial seizures and several diverse disorders. The drug has a relatively safe profile and is well tolerated; however, awareness is required to monitor the patient's medication, its misuse, and how to approach better patient fate. Despite the enormous scientific hypothesis encircling the drug, there is a requisite to research further about the novelty of the drug. The review delineates the drug profile, synthesis, pharmacology, ADME properties, and computational study of gabapentin.